However, certain trials have described decompensated HF after anti-TNF initiation, particularly in patients with pre-existing left ventricular dysfunction; thus some societies recommend avoiding anti-TNF therapy in patients with established moderate-to-severe HF [198]. The gene discussed is TNF; the disease is hydrops fetalis.